HOW GW7647 CAN SAVE YOU TIME, STRESS, AND MONEY.

All enrolled sufferers who received a minimum of a single dose of zosuquidar or placebo throughout induction have been monitored with the occurrence of adverse activities (439 patients, 219 on zosuquidar and 210 on placebo). The most common adverse functions were being related to the duration of extended and substantial myelosuppression as is antic